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Abstract
Evidence is emerging that resveratrol (RV), a polyphenolic phytoaxelin present in dietary sources including red wine, may protect against
atherosclerosis and cardiovascular disease by enhancing the integrity of the endothelium. In this study, the possibility that such beneficial
effects of RV may arise from a modulation of protein kinase C (PKC)-mediated signaling was investigated by determining the effects of RV
on the in vitro activities of PKC isozymes. It was found that the Ca2 +-dependent activities of membrane-associated PKCa induced by either
phorbol ester or diacylglycerol were potently inhibited by RV, each with an IC50 of f 2 AM. The inhibitory effect of RV was also observed
for conventional PKChI, whereas the activities of novel PKCq and atypical PKC~ were each unaffected. The inhibition of PKCa activity was
found to be competitive with respect to phorbol ester concentration but noncompetitive with respect to Ca2 + and phosphatidylserine
concentrations, suggesting that the RV may compete for phorbol ester-binding to the C1 domains. Supporting this, it was found that RV
bound to a fusion peptide containing the C1A and C1B domains of PKCa. Similar to the effects of diacylglycerol and phorbol ester, the
interaction of RV with the C1 domains induced the association of PKCa with membrane lipid vesicles, although this did not result in
activation. Overall, the results suggest that the inhibitory effect of RV on PKC activity, and therefore on the associated signaling networks,
may, in part, underlie the mechanism(s) by which this agent exerts its beneficial effects on endothelial and cardiovascular function.
Furthermore, the effects of RV on these signaling networks are predicted to differ according to the cellular localization and the regulating
PKC isozyme.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Coronary heart disease (CHD) remains the foremost
cause of death in developed countries including the United
States [1]. Common examples of vascular pathologies that
are encompassed by CHD include myocardial infarction and
angina pectoris, each of which results from a decrease in the
diameter of heart vessel lumens due to the atherosclerotic
deposition of fatty cholesterol-rich deposits. Atherosclerosis
is therefore positively correlated with increased serum
cholesterol levels, high blood pressure and high dietary
saturated fat intake [2,3]. However, a number of epidemio-
logical studies have shown that some countries that have
high dietary risk factors for CHD, in particular southern
France, have a relatively decreased occurrence of this
disease [4,5]. Primary dietary factors that exert beneficial
effects on cardiovascular function, in what has been termed
the ‘‘French Paradox,’’ have been identified as certain
polyphenolic components of red wine. In particular,
3,5,4V-trihydroxy-trans-stilbene, or resveratrol (RV), which
is found in grape skins, has attracted considerable attention
based on its observed cardioprotective effects [6–18].
The cellular mechanisms by which RV exerts an anti-
atherogenic and thus cardioprotective effects have been
suggested to include the stimulation of endothelial vaso-
relaxation through stimulation of the NO-cGMP cascade
[19], the inhibition of LDL oxidation [20,21], inhibition of
vascular NADH/NADPH oxidase [22], and platelet aggre-
gation and synthesis of eicosanoids [23–25]. RV has been
shown to inhibit the production of reactive oxygen species
(ROS) in rat macrophages and human monocytes and
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granulocytes [26–28]. Thus, RV is a potent scavenger of
free radicals, which have been identified as a key factor in
the production of oxidized LDL and in lipid peroxidation
[29,30]. RV also has anti-inflammatory properties [31,32],
which are manifested as inhibition of ICAM-1 and VCAM-
1 expression and the attachment of monocytes to endothelial
cells, an inhibition of the lipopolysaccharide (LPS)-induced
synthesis of TNF-a and IL-1-h, and a release of IL-6 from
monocytes [33]. Elsewhere, it was shown that RV inhibits
the generation of NO, the activation of NF-nB and the
expression of iNOS [34]. In addition to effects on cytokine
production, RV has also been shown to suppress the growth
of endothelial cells, as well as cells derived from other
tissues [31,35,36]. For example, the proliferation of bovine
aortic endothelial cells was reported to be potently inhibited
by RV—an effect that has been suggested to counteract
atherogenic effects [35].
Recent studies have indicated that the effects of RV on
the processes of cytokine production, endothelial cell
growth and proliferation, and also on changes in cell
morphology, likely result from an impact on elements of
the signaling networks that regulate them. In particular, it
has been shown that RV can interfere with signaling
cascades by modulating kinase and other enzyme activities.
Thus, RV was shown to inhibit the proliferation of BPAEC
cells and also to induce changes in morphology by a
mechanism involving an impact on filamentous-actin (F-
actin) and microtubule assembly, intracellular calcium lev-
els, and on tyrosine kinase activities [37]. Effects of RV on
tyrosine phosphorylation have also been implicated in the
inhibition of proliferation and the contraction of coronary
artery smooth muscle induced by endothelin-1, which is an
important mediator of cardiovascular disorders [38]. This
effect appeared to be mediated by an inhibition of MAPK
activity, phosphorylation and nuclear localization.
Evidence that protein kinase C (PKC)-mediated signal-
ing, in particular, may be a target for RV has been presented
in a recent study that showed that the stilbene blocked the
phorbol ester-induced induction of COX-2 gene promoter
activity mediated by AP-1 [39]. Consistent with this,
another study showed that RV directly inhibited the activity
of MAPK and, consequently, the phosphorylation of down-
stream kinases that lead to AP-1 activation [38]. Another
recent study also provided evidence for an inhibition of AP-
1 transcriptional activity mediated by the MAPK pathway,
and showed that additional signaling molecules up-stream
of Raf-1 or MEKK1, including PKC, may be targeted by
RV [40]. The decreased production of COX-2 resulting from
the inhibition of AP-1 was shown to coincide with an
inhibition of the production of prostaglandin E2, which
was suggested to provide a possible mechanism for the
anti-inflammatory and cancer chemopreventative properties
of RV [31]. In connection with the latter, RV has been
shown to antagonize phorbol ester-induced tumor promo-
tion in the mouse skin model, providing further evidence for
an impact on PKC-mediated signaling [31].
The minimal 12 isozymes that constitute the PKC family
can be distinguished on the basis of the presence or absence
of structural motifs that direct cofactor requirements for
membrane-association and activation [41]. Thus, the ‘‘con-
ventional’’-a, -hI, -hII and -g (cPKC) isozymes contain a
conserved C1-domain that harbors the phorbol ester and
diacylglycerol binding sites, and a C2-domain that binds
two Ca2 +-ions. The ‘‘novel’’ -y, -q, -D and -u (nPKC)
isoforms contain a C1-domain but lack a functional C2-
domain, which results in the membrane association and
activation of these isoforms being Ca2 +-independent. In
the case of ‘‘atypical’’ PKC~ and  L/E (aPKC), neither
the C1 nor the C2 domains are functional and these isoforms
are therefore unresponsive to Ca2 + and phorbol esters or
diacylglycerols. A general property of all of the PKC
isozymes is that they each become active upon translocating
to membranes containing anionic lipids such as phosphati-
dylserine [41].
Support for the notion that RV effects on PKC-mediated
signaling might involve a direct effect on PKC activity has
been presented in a number of recent in vitro studies [42–
46]. However, whereas each study observed a weak inhib-
ition of PKC activity by RV, the potency of the effect and
the mechanism proposed for the effect appear to differ
markedly according to the purity of the PKC isozyme
preparations used and whether or not activators required
for the optimal membrane association and activation of PKC
were included in the assay systems employed. Therefore,
the question whether an impact of RV on the activities of
PKC isozymes and therefore on PKC mediated signaling
networks might underlie some of the beneficial effects of the
stilbene on cardiovascular function remains unresolved.
In this study, the mechanism of the effects of RV on the
activities of purified recombinant PKC isozymes induced by
association with model lipid vesicle membranes was inves-
tigated using an in vitro assay system in which the cofactor-
and activator-concentration dependencies for activation
were systematically varied. It was found that RV inhibited
membrane-associated PKCa activity within a concentration
range relevant to the cellular effects of the stilbene
[28,29,31,47–49]. This effect was observed for conven-
tional PKCa and PKChI, but not novel PKCq or atypical
PKC~ , and resulted from competition for activator binding
to the C1 domains. The results support the contention that
the beneficial effects of RVon endothelial cell function may,
in part, be mediated by an impact on membrane-associated
PKC activity and the associated signaling networks.
2. Materials and methods
Adenosine 5Vtriphosphate (ATP) was from Boehringer
Mannheim (Indianapolis, IN). [g32P]ATP was from New
England Nuclear (Boston, MA). 1-Palmitoyl-2-oleoylphos-
phatidylcholine (POPC), bovine brain phosphatidylserine
(BPS) and 1,2-dioleoyl-sn-glycerol (DAG) were from
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Avanti Polar Lipids, Inc. (Alabaster, AL). Peptide substrates
were custom synthesized by the peptide synthesis facility of
the Kimmel Cancer Institute at Thomas Jefferson Univer-
sity. 4h-12-O-Tetradecanoylphorbol-13-acetate (TPA) was
obtained from Sigma (St. Louis, MO) and RV was from
Calbiochem (San Diego, CA). All other chemicals were of
analytical grade and obtained from Fisher Scientific (Pitts-
burgh, PA).
2.1. Expression and purification of PKC isozymes and C1
domains
Recombinant PKCa, -hI and -q (rat brain) were prepared
using the baculovirus Spodoptera frugiperda (Sf9) insect
cell expression system [50] and purified to homogeneity
using published procedures [51,52]. PKC~ was overex-
pressed in Sf9 cells as fusion protein containing a (His)6
attached to the C terminus, and a fusion protein correspond-
ing to the C1A and C1B domains of PKCa (aC1A–C1B)
was prepared as described previously [52,53]. To provide
structural stability, solubility, and to aid purification, the
aC1A–C1B peptide was tagged with glutathione-S-trans-
ferase (GST) at the N terminus and with (His)6 at the C
terminus. The isolation and purification of the tagged
protein was performed using previously described methods
[52,53].
2.2. Measurements of PKC activity
PKC isozyme activities were assayed by measuring the
rate of phosphate incorporation into a peptide substrate, as
described previously [54]. For the ‘‘conventional’’ PKC
isoforms, a peptide corresponding to the phosphorylation
site domain of myelin basic protein [QKRPSQRSKYL,
MBP4–14] was used as the substrate, whereas assays of
‘‘novel’’ PKC and ‘‘atypical’’ PKC~ activity used a peptide
corresponding to the pseudosubstrate region of ‘‘novel’’
PKCq (q-peptide), in which the single alanine residue was
replaced by serine [55–57]. Conventional PKC isozyme
activities were measured using an assay (75 Al) consisting of
50 mM Tris/HCl (pH 7.40), POPC/BPS large unilamellar
vesicles (LUV), CaCl2 (0.1 mM), MBP4–14 (50 AM), TPA
or DAG (0.3 and 4 mol% of the total lipid concentration,
respectively, or as indicated), and RV at the indicated
concentrations added from a 100 mM Me2SO stock. The
maximum concentration of Me2SO in the assay systems
used was 0.2% v/v, which was found in separate control
experiments to have negligible effects on PKC isozyme
activities. The activities of novel PKCq and atypical PKC~
were measured using an identical assay system, except that
ethyleneglycol-bis-(h-aminoethyl ether)-N,N,NV,NV-tetraace-
tic acid (EGTA) (0.1 mM) and peptide-q (50 AM) were
substituted for CaCl2 and MBP4–14, respectively. The LUV,
which were of diameter 100 nm, total lipid concentration
150 AM, and POPC/BPS molar ratio 4:1, unless stated
otherwise, were prepared in a buffer consisting of 50 mM
Tris/HCl (pH 7.40) and 0.1 mM EGTA as described
previously [58]. In experiments where the level of BPS in
LUV was varied or where DAG or TPA was added, each of
these additions was done at the expense of POPC while
keeping the total lipid concentration constant. The Ca2 +-
concentration dependencies of PKCa activity were deter-
mined by adding Ca2 + as CaCl2 at a level calculated to yield
the required free level of Ca2 + when buffered by 0.1 mM
EGTA [59]. After thermal equilibration to 30 jC, assays
were initiated by the simultaneous addition of the required
PKC isoform (0.3 nM) along with 5 mM Mg2 +, 100 AM
ATP, 0.3 ACi [g32P] ATP (3000 Ci/mmol), and terminated
after 30 min with 100 Al of 175 mM phosphoric acid.
Following this, 100 Al was transferred to P81 filter papers,
which were washed three times in 75 mM phosphoric acid.
Phosphorylated peptide was determined by scintillation
counting. The linearity of this assay system has been
confirmed previously [54].
2.3. Binding of RV to the C1 domains of PKCa
Fluorescence measurements were made at 30 jC using a
SpectraMaxk Gemini plate reader (Molecular Devices,
Inc., Sunnyvale, CA). The interaction of RV with the
aC1A–C1B fusion peptide was determined by utilizing
the apparent proportionality between the emission fluores-
cence intensity and the magnitude of a blue shift in the
emission maximum of RV with the dielectric of its environ-
ment (i.e. hydrophobicity), as has been observed previously
for the interaction of dansyl-lysine with membranes [60].
Initially, the excitation maximum of RV (1 AM) in water was
estimated from the absorbance spectrum (not shown) to be
330 nm (molar extinction coefficient f 9000 M 1 s 1).
The emission spectra of RV, obtained upon excitation at 330
nm, were then measured in a series of water–dioxane
mixtures containing an increasing mole fraction of dioxane.
Binding of RV to the aC1A–C1B domain was then
measured from the corresponding increase in fluorescence
intensity at the emission maximum of RV, as a function of
RV concentration.
2.4. Interaction of PKCa with membranes
Determinations of the interaction of PKCa with mem-
branes were performed based on surface plasmon resonance
(SPR) measurements, using a BIAcorek 2000 (Biacore,
Inc. Piscataway). The hydrophobic surface of a pioneer L1-
chip (Biacore) was initially conditioned with a 15 Al
injection of 50 mM CHAPS (5 Al/min). Following this,
BPS/POPC LUV, prepared in an identical manner to those
used in the activity assays (see above) except that the total
lipid concentration was 500 AM and the buffer used con-
tained 150 mM NaCl, were injected at a flow rate of 5 Al/
min. For experiments involving TPA, the phorbol ester was
added to an aliquot of the 500 AM LUV to a level of 1.5 AM
prior to injection so as to ensure that the mole fraction of
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TPA in the LUV captured on the L1-chip surface was
identical to that used in the PKC activity assays (0.3
mol%). The resultant lipid surface was then conditioned
by successive 15-Al injections of NaOH (10 mM) and
glycine buffer (10 mM, pH 1.5). PKCa (5 nM) was then
injected over the surface at a flow rate of 50 Al/min in a
solution containing 50 mM Tris/HCl (pH 7.40), Mg2 + (5
mM), ATP (100 AM), MBP4–14 (50 AM), with or without
Ca2 + (0.1 mM) and RV (50 AM), as indicated. The surface
was regenerated by two successive 10-Al injections of 0.1%
v/v Triton X-100. After subtraction of the contribution of
bulk refractive index changes and nonspecific interactions
of PKC isozymes with the L1-chip, which were typically
less than 1% of the total signal, the individual association
(ka) and dissociation (kd) rate constants were obtained by
global fitting of data to a 1:1 Langmuir binding model using
BIAevaluationk (Biacore). These values were then used to
calculate the dissociation constant (KD). The values of
average squared residual (v2) obtained were not signifi-
cantly improved by fitting data to models that assumed
bivalent or heterogeneous interactions. In a separate control
experiment (results not shown), it was found that the
contribution of mass transport to the observed values of
KD was negligible, based on the observation that these
values were independent of flow rate within a range
encompassing that used (10 to 50 Al min 1).
3. Results
In order to investigate the mechanism of the effects of
RV on PKC isozyme activities, in vitro assays were utilized
in which the levels of RV, phorbol ester, Ca2 + and PS were
systematically varied. PKC activities were determined using
assays containing LUVof defined size and composition and
peptide substrates, and have been shown previously to be
free from aggregation, which might otherwise lead to
complications in the interpretation of RV effects [54].
3.1. Concentration-dependent effects of RVon PKC isozyme
activities
The effects of RV on PKCa activity induced by PS and
Ca2 + alone, or with TPA or DAG, are shown in Fig. 1A. It
was found that the ‘‘basal’’ activity of PKCa induced by
Ca2 + (0.1 mM) and PS (20 mol%) alone, which results from
the partial membrane-association of the isozyme [61], was
inhibited by RV in a concentration dependent manner (Fig.
1A, inset). However, under these conditions it was found
that PKCa activity was only inhibited at relatively high RV
concentrations and that this was not complete even at the
highest levels of RV used (100 AM). By contrast, the activity
of PKCa induced by Ca2 + and PS in the presence of TPA
(0.3 mol%) or DAG (4 mol%), under which condition the
isozyme is fully membrane-associated [61], was potently
inhibited by RV with IC50 values of 2.0F 0.2 and 2.8F 0.2
AM, respectively. Each of the dose–response curves fitted
with least error to an equation that assumed the existence of
a single binding site for RV. The inhibitory effect of RV was
found to be relatively specific for PKCa (Fig. 1B). Thus,
whereas RV also inhibited the TPA-induced activity of
membrane-associated PKChI, which is also classified as a
conventional PKC isoform, the potency of this effect was
Fig. 1. Effects of RV on PKC isozyme activities induced by membrane
association. Panel A: The activity of PKCa was measured as a function of
RV concentration using an in vitro assay containing BPS/POPC LUV (4:1
molar, 150 AM total lipid concentration) and 0.1 mM Ca2 + alone (INSET)
and with either 0.3 mol% TPA (E) or 4 mol% DAG (n). Panel B: The
effects of RV on conventional PKChI (n), novel PKCq (E) and atypical
PKC~ (x) activities compared to that on PKCa (.) activity were measured
as a function of RV concentration. Peptide-q was used as a substrate for
PKCq and PKC~ in place of the MBP4– 14 peptide used for PKCa. Values
are meansF S.D. obtained from experiments carried out in triplicate. The
solid curves represent fits of activity against concentration data to a
hyperbolic function that assumed a single site of interaction [61]. See
Materials and methods for other details.
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reduced f 50-fold (IC50 = 105F 10 AM) compared to
PKCa. Strikingly, the activities of both novel PKCq,
induced by association with membranes containing TPA,
and atypical PKC~ , induced by membrane-association with-
out TPA, were each unaffected by RV, even at levels in
excess of 500 AM.
3.2. Effects of RV on the TPA-, PS- and Ca2+-concentration
dependencies of PKCa activation
The results shown in Fig. 1A indicate that the potency of
the inhibitory effects of RV on PKCa activity may differ
depending on presence or absence of phorbol ester. The
effect of increasing concentrations of RV (0, 1, 10, 50 AM)
on the concentration dependence of TPA-induced PKCa
activity, shown in Fig. 2A, was to shift the concentration–
response curves to higher TPA levels, rather than to
decrease the maximal level of activity attained. Thus, the
presence of 1 AM RV resulted in a shift in the midpoint of
the TPA-dose–response curve from 50F 1.2 to 150F 8
nM. These results suggest that the inhibitory effect of RVon
membrane-associated PKCa activity may result from com-
petition for TPA-binding to the isozyme.
The concentration–response curves for PKCa activation
by Ca2 + (Fig. 2B) and PS (Fig. 2C), determined in the
presence of a saturating level of TPA (0.3 mol%), were each
found to be similar to those reported previously [61–63].
By contrast to the effects of RV on the TPA-concentration–
response curves, the presence of increasing levels of RV (0,
5, 50 AM) on the Ca2 +- and PS-concentration-dependencies
of membrane-associated PKCa activation resulted in a
decrease in the maximal level of activity attained rather
than a shift in the midpoint of the curve (Fig. 2B and C).
Thus, the inhibitory effect of RV appeared to be noncompe-
titive with respect to Ca2 +- and PS-induced activation.
3.3. Interaction of RV with the C1 domains of PKCa
The above results suggest that the inhibitory effects of RV
on TPA-induced PKCa activity may result from competition
with the phorbol ester for binding to the activator binding
sites within the C1 domains. In order to investigate this, the
interaction of RV with a fusion protein containing the C1
domains of PKCa (aC1A–C1B) was determined by utilizing
the apparent sensitivity of the fluorescence properties of RV
to changes in the hydrophobicity of its environment. Thus, as
shown in Fig. 3A, excitation of RV in water at 330 nm yielded
an emission maximum (kmax) at 400 nm. Increasing the
hydrophobicity of the RV solution by incrementally increas-
ing the mole fraction of dioxane in a series of water–dioxane
binary solvents resulted in a blue shift in kmax and also to an
 
Fig. 2. Concentration-dependent effects of RV on TPA-, Ca2 +- and PS-
concentration dependencies of PKCa activity. Panel A: PKCa activities
were measured as a function of membrane-concentration of TPA in an assay
containing BPS/POPC LUV (4:1 molar) of 150 AM total lipid concentration
and 0.1 mM Ca2 +, either in the absence of RV (.), or with RVat levels of 1
AM (n), 10 AM (E) or 50 AM (x). Panel B: PKCa activities were
measured as a function of free Ca2 + concentration with BPS/POPC LUV
(4:1 molar) and 0.3 mol% TPA, either without RV (.) or with RV at levels
of 10 AM (n), or 50 AM (E). Panel C: The PS-concentration dependence
of PKCa activity was measured in the presence of 0.3 mol% TPA and 0.1
mM Ca2 +, and LUV in with the mole fraction (XPS) of BPS was varied
while keeping the total lipid concentration constant, either without RV (.),
or with RV at levels of 10 AM (n) or 50 AM (E). Values are meansF S.D.
Experiments were repeated at least three times. See Materials and methods
for other details.
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increase in the fluorescence intensity at kmax (Fmax). It was
found that the value of kmax for RV bound to the aC1A–C1B
domain, obtained by subtraction of spectra obtained in the
presence of the aC1A–C1B fusion peptide from that
obtained in the presence of a peptide composed only of
GST and His6, was again shifted to a shorter wavelength and
that the value of Fmax was again increased compared to
values obtained for RV in pure water (Fig. 3B). The value
of Fmax was found to increase as a function of the concen-
tration of RV, whereas the value of kmax remained constant.
These results suggest that RV interacts with the hydrophobic
activator binding sites within the aC1A–C1B domain. Con-
sistent with this, as shown in Fig. 3B (inset), the presence of
increasing levels of TPA was found to result in a concen-
tration-dependent decrease in the value of Fmax.
3.4. Effect of RV on PKCa binding to membranes
In order to investigate whether the inhibitory effect of RV
on membrane-associated PKCa activity may have been due
to an attenuation of the interaction of the isozyme with
membranes, the effects of RV on membrane-association
were determined using SPR (Fig. 4). Results obtained in
the absence of RV (Fig. 4A) indicated that a negligible level
of membrane-association of PKCa occurred in the absence
of both Ca2 + and TPA (dashed line), as reported previously
[61]. Also consistent with previous results [61,64,65], the
presence of TPA alone was found to result in a low level of
binding of PKCa to the BPS/POPC LUV (dotted line), the
affinity for which was markedly enhanced by the addition of












Fig. 3. Interaction of RV with a fusion peptide containing the C1A and C1B domains of PKCa (aC1A–C1B). Panel A: Emission fluorescence spectra of RV
(excitation at 330 nm) were obtained in water–dioxane binary mixed solvents of increasing mole fraction of dioxane. Panel B: Emission spectra of RV upon
excitation at 330 nm were obtained for a series of aC1A–C1B domain concentrations. The change in fluorescence of RV due to binding to the aC1A–C1B
domain was isolated by subtraction of spectra obtained in the absence of the domain from that obtained in the presence of the domain for each aC1A–C1B
concentration. Inset: Displacement of RV binding to the aC1A–C1B domain by TPA. Values of Fmax for RV (2.8 AM) were measured as a function of TPA
concentration. The data are representative of experiments carried out three times. See Materials and methods for other details.
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f 50-fold decrease in the value of KD, which corresponded
primarily to an increase in ka, rather than a decrease in kd
(Table 1).
The presence of a fixed concentration of RV alone (50
AM) was found to induce the association of PKCa with
BPS/POPC LUV (Fig. 4B), as was found for TPA alone
(Fig. 4A). However, the affinity the interaction of PKCa
with LUV induced by RV was found to be f 10-fold lower
than that induced by TPA (Table 1). Interestingly, similar to
the synergistic effect of TPA in combination with Ca2 + on
PKCa binding to membranes, the presence of RV together
with Ca2 + was found to result in a f 30 fold decrease in
the value of KD compared to that obtained for obtained for
PKCa binding to LUV in the presence of RV alone (Table
1). However, the maximal level of RV-induced binding of
PKCa to LUV was unaffected by the presence of Ca2 + (Fig.
4B). The level of PKCa binding to LUV induced by RV was
similar to that induced by saturating levels of TPA and
Ca2 +, a condition that has been shown previously to be
sufficient for the full membrane-association of this isozyme
[61]. It was found that the value of KD obtained for PKCa
binding to LUV in the presence of Ca2 +, TPA and RV
together was reduced by f 10-fold compared to that
obtained with TPA and Ca2 +, and similar to that obtained
with RV and Ca2 +. The maximal level of binding of PKCa
to LUV induced by Ca2 +, TPA and RV was again similar to
that observed in the presence of Ca2 + and TPA (compare
Fig. 4A with Fig. 4B).
4. Discussion
In this study, the mechanism of the effects of RV on the
activities of PKC isozymes induced by association with
membranes was investigated. It was found that the activities
of conventional PKCa and PKChI, but not novel PKCq and
atypical PKC~ , were each potently inhibited by RV by a
mechanism involving the displacement of phorbol ester- or
DAG-binding to the C1 domains. The levels of RV required
for this inhibitory effect were within a concentration-range
encompassing those that have been shown previously to
induce cellular effects that may underlie some of the car-
dioprotective properties of the stilbene [28,29,31,47–49].
A central aspect of the mechanism by which conven-
tional PKC isozymes become active is their initial trans-
location to the membrane, which is mediated by two parallel
Fig. 4. Effect of RV on the interaction of PKCa with membrane lipid
vesicles. PKCa binding to membranes was quantified using SPR by
flowing the isozyme (5 nM) over a L1-chip surface to which BPS/POPC
LUV identical to those used in activity assays (see legend to Fig. 1) had
been captured. PKCa was injected in the absence (Panel A) or presence
(Panel B) of RV (50 AM), with (dotted line) or without (dashed line) 0.1
mM Ca2 +, over LUV composed of BPS/POPC alone or containing 0.3
mol% TPA (solid line). The data were initially corrected for bulk shifts in
response due to refractive index differences between buffers, and are
representative of experiments carried out at least five times. Other details
are given in Materials and methods.
Table 1
Analysis of the effects of RV on the interaction of PKCa with BPS/POPC membranes using SPR
Condition ka (M
 1 s 1) kd (s
 1) KD (M) v
2
PKCa+TPA (6.69F 0.90) 104 (1.08F 0.02) 10 2 (1.62F 0.24) 10 7 1.62
PKCa+TPA+Ca2 + (1.86F 0.05) 106 (7.14F 0.05) 10 3 (3.84F 1.30) 10 9 5.70
PKCa+RV (1.05F 0.14) 104 (1.42F 0.03) 10 2 (1.42F 0.21) 10 6 1.90
PKCa+RV+Ca2 + (2.38F 0.96) 105 (1.21F 0.03) 10 2 (5.08F 0.80) 10 8 5.22
PKCa+RV+TPA+Ca2 + (2.21F 0.27) 105 (9.08F 0.25) 10 3 (4.10F 1.15) 10 8 1.76
BPS/POPC LUV, incorporating 0.3 mol% TPAwhere required, were initially immobilized on the surface of a L1 sensor chip, and PKCa was then injected over
the surface in the presence or absence of 0.1 mM Ca2 + and 50 AM RV, as indicated. The dissociation constants (KD) were obtained from the ratio of the
association (ka) and dissociation (kd) rate constants, derived from global fits of response against time data to a 1:1 Langmuir binding model. Further details are
given in Materials and methods and in the legend to Fig. 4.
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but independent interactions [65]: The isozymes initially
bind with low affinity to the membrane-surface through an
interaction between the Ca2 +-binding sites of the C2 domain
and the head groups of anionic phospholipids, in particular
PS. The affinity of membrane-association is then further
increased by the insertion of the C1 domains into the
membrane-interior, which is facilitated by DAG or phorbol
ester binding. The combined interaction of the C1 and C2
domains with the membrane provides the energy to drive the
conformational change that results in activation, which
involves the folding out of the pseudosubstrate region from
the active site [65]. The observed inhibitory effects of RVon
conventional PKC activity may therefore potentially result
either from an impact on the association of PKC with
membranes or on the conformational change in the mem-
brane-associated enzyme that results in activation.
The observation that RV both bound to a hydrophobic site
within the aC1A–C1B peptide and competed with TPA for
binding to this site suggests that the inhibition of PKC
activity results from an interaction of RV with the C1
domains. This was also indicated by the observation that
the inhibitory effect of RVon PKCa activity corresponded to
a shift in the TPA dose–response curves for activation rather
than a decrease in the maximal level of activity attained.
Furthermore, the finding that the inhibitory effect of RV
corresponded to a decrease in the amplitude, rather than a
shift in the midpoint of the Ca2 +- and PS-concentration–
response curves, suggests that the initial interaction of PKCa
with the membrane that is mediated by the C2 domain is
unaffected by RV. The observation from SPR measurements
that the presence of RV resulted in the recruitment of PKCa
to LUV, and that Ca2 + increased the affinity of this inter-
action, also indicates that the inhibitory effect of RV on
PKCa activity does not result from an attenuated level of
membrane-association. Indeed, the data suggest that the
interaction of RV with the C1 domains may promote mem-
brane-insertion by a similar mechanism to phorbol ester
binding, which has been suggested to result from the capping
of a hydrophilic base of the activator-binding site to form a
contiguous hydrophobic surface [66]. However, the results
also show that the interaction of RV with this site is not
equivalent to that of phorbol esters or diacylglycerols in that
it does not result in activation. Taken together, these obser-
vations imply that the energy derived from the penetration of
the C1 domains into the membrane-interior, which is appa-
rently induced by both phorbol ester and RV, is not sufficient
to release the pseudosubstrate from the active site, and that
this requires additional conformational changes in the C1
domains that are induced by phorbol ester but not RV. In
connection with this, the results of a previous study from this
laboratory indicated that phorbol ester binding to the C1
domain of PKCa results in a structural rearrangement in the
domain which is involved in the overall conformational
change in the PKC molecule that results in activation [67].
The observation that the inhibitory effect of RV was
confined to conventional PKCa and PKChI initially sug-
gests that the inhibitory RV binding sites may not be present
on the novel PKCq and atypical PKC~ isozymes. Whereas
PKC~ lacks a functional activator-binding site within its
single C1 domain [68], and therefore may also be expected
to lack a binding site for RV, this is not the case for PKCq,
which is similar to PKCa in containing two C1 domains that
bind activators. The differences in the effects of RV on
PKCa and PKCq may therefore result from differing spe-
cificities of their C1 domains with respect to RV binding.
Furthermore, the observation that the potency of the inhib-
ition of PKChI activity by RV was f 50-fold less than for
PKCa, even though the C1 domains of these isozymes share
considerable homology, suggests that relatively subtle
changes in C1 domain structure may have large effects on
their specificities for RV binding. The interaction of phorbol
esters with the binding pocket within the C1 domain has
been shown previously to be mediated in part by hydrogen
bonding [66,69–71]. It is therefore possible that the
hydroxyl moieties of RV may compete for these interactions
resulting in the observed displacement of phorbol ester
binding and inhibition of activity. Consistent with this,
studies from this laboratory have shown that n-alkanols
can also compete for phorbol ester binding to the C1
domains [72].
Comparisons of the effects of RV on PKC isozyme
activities observed in this study with those from previous
work indicate that the potency of the inhibitory effects are
markedly dependent on the conditions under which activa-
tion was induced [42–46,73]. Thus, in a previous study it
was observed that RV weakly inhibited the ‘‘basal’’ level of
conventional PKC isozyme activity measured using an assay
that contained PS and Ca2 + but which excluded diacylgly-
cerol or phorbol esters [43], as was confirmed here (Fig. 1,
inset; EC50>100 AM). The level of RV required for an
inhibitory effect under these conditions has been shown to
be cytotoxic [74], and also appears to be in large excess of
that likely to be present in tissues after dietary intake [75–
78]. Therefore, it is unlikely that this sub-optimally activated
form of PKC participates in the cellular effects of RV.
However, it is shown here that inducing optimal association
with PS containing membranes, and thus activation by
including phorbol ester or diacylglycerol in the assay, results
in a large increase in the inhibitory potency of RV (EC50f 2
AM). Consistent with this, it was shown previously [43] that
PKC activity induced by interaction with the arginine-rich
substrate, protamine sulfate, which circumvents the PS, Ca2 +
and activator requirements for optimal activation, was also
potently inhibited by RV (EC50f 10 AM).
The mechanism of the inhibitory effect of RV may also
differ according to the activating conditions used. Thus, a
previous study showed that the observed weak inhibition of
‘‘basal’’ conventional PKC activity induced by PS and Ca2 +
alone involved competition for ATP binding, whereas the
potent inhibition of optimal membrane-associated activity
was found here to result from competition for activator
binding to the C1 domains. Consistent with this, the
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previous study showed that the inhibition of optimal activity
induced by protamine sulfate was noncompetitive with
respect to ATP [43]. Interestingly, it was suggested that
the inhibitory effect of RV on protamine sulfate activity
involves an interaction with hydrophobic sites that are
exposed upon activation which, based on the results of the
present study, can be speculated to correspond to the C1
domains. The finding that the activities of PKCq and PKC~
were each unaffected by RV also argues against the possi-
bility that the observed inhibitory effect of RV on optimal
membrane-associated PKC activities may have involved
competition for nucleotide binding, since the catalytic
domains of these PKC isozymes share a high degree of
structural homology.
Recently, it was reported that the autophosphorylation of
PKC isozymes induced by PS, diacylglycerol and Ca2 + was
unaffected by RV, even though based on the present results
these conditions would have been expected to induce
optimal activation [44]. This apparent variation from the
potent inhibitory effect observed here likely reflects differ-
ences in the levels of diacylglycerol and PS present in the
assay systems used. Thus, whereas in the present study
diacylglycerol was present at a level of 4 mol% in LUV
containing 20 mol% PS, in the previous study it was
incorporated at a fixed level of 24 mol% in vesicles that
were composed purely of PS. Based on the observation of
this study that the inhibition of PKC activity results from
competition between RV and phorbol ester (or diacylgly-
cerol) for binding to the C1 domains, such an increase in the
level of diacylglycerol may account for the apparent
decrease in the inhibitory potency of RV.
In conclusion, the levels of RV required to inhibit mem-
brane-associated PKCa activity appear to be within a con-
centration range that is consistent with those reported to elicit
cellular effects likely to be important in the physiological
responses to the stilbene [28,29,31,47–49]. In particular, by
virtue of the centrality of PKC in signaling cascades that
regulate the functioning of endothelial cells, the inhibitory
effects of RV on PKC activities are likely to be important
determinants in the mechanisms by which RV exerts its
beneficial effects on cellular and cardiovascular function.
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